94 related articles for article (PubMed ID: 5159600)
1. [Effect, on gastric absorption, of a new molecule with mucopoietic activity, 2-)p-methylsulfonylphenyl)-imidazo (1,2-a) pyridine, used in therapy of gastroduodenal diseases].
Barlattani M
Clin Ter; 1971 Dec; 59(5):417-30. PubMed ID: 5159600
[No Abstract] [Full Text] [Related]
2. [Use of a new drug in the treatment of gastroduodenal diseases].
Bagliani A; Borri P
Minerva Gastroenterol; 1972; 18(3):165-74. PubMed ID: 4614114
[No Abstract] [Full Text] [Related]
3. Pharmacology of zolimidine (2-(p-methylsulfonylphenyl)-imidazo (1,2-a) pyridine) a new non-anticholinergic gastroprotective agent. IV) Enhancement of gastric mucus production in different experimental models.
Murmann W; Carminati GM; Cattaneo R
Panminerva Med; 1974 Oct; 16(10):347-59. PubMed ID: 4155797
[No Abstract] [Full Text] [Related]
4. [Composition of the gastric mucus of normal rats with stress ulcers treated with 2-(p-methylsulfonylphenyl-)- imidazo (1,2-a)- pyridine].
Pallavicini G; Cetta G; Calatroni
Boll Soc Ital Biol Sper; 1971 Oct; 47(20):644-7. PubMed ID: 5143113
[No Abstract] [Full Text] [Related]
5. [The pathogenesis of peptic ulcer of the stomach and duodenum].
Samsonov VA
Arkh Patol; 1972; 34(10):3-11. PubMed ID: 4573521
[No Abstract] [Full Text] [Related]
6. [Clinical study on 20 gastroduodenal ulcer patients treated with 2-p-methyl sulphonylphenyl imidazol (1,2-alpha) pyridine (zolimidine)].
García Alvarez M; Ramírez Armengol JA
Rev Clin Esp; 1972 Aug; 126(4):353-6. PubMed ID: 4638610
[No Abstract] [Full Text] [Related]
7. Study of the concentration of mucoprotein in the gastric juice from healthy subjects and gastroduodenal patients before and after treatment with a gastro-protective drug, zolimidine.
Camarri E; Zaccherotti L; D'Alonzo D
Arzneimittelforschung; 1972 Apr; 22(4):768-72. PubMed ID: 5068258
[No Abstract] [Full Text] [Related]
8. Effect of zolimidine, a derivative of imidazo (1,2-a) pyridine, on the gastric mucosa of patients with gastric disorders.
Celli L; Clementi F; Santagostino C
Curr Ther Res Clin Exp; 1975 Jul; 18(1 pt 2):105-23. PubMed ID: 809228
[No Abstract] [Full Text] [Related]
9. [Zolimidine. Evaluation of the symptomatic effect in patients with gastroduodenal diseases].
Rizzi B; Giacomini F; Bandini V
Minerva Gastroenterol; 1975; 21(4):258-65. PubMed ID: 778658
[No Abstract] [Full Text] [Related]
10. [Evaluation of the therapeutic activity of CR 242 or Xylamide in the treatment of gastric and duodenal ulcers and of gastroduodenitis].
Bellomo A; Strobbia R; Manzoni A
Minerva Med; 1969 Mar; 60(23):1024-31. PubMed ID: 5781328
[No Abstract] [Full Text] [Related]
11. [Results obtained with Dogmagel in the treatment of gastroduodenal ulcer and gastroduodenitis].
Sánchez García-Moreno I
Rev Esp Enferm Apar Dig; 1974 Dec; 44(7):743-6. PubMed ID: 4445556
[No Abstract] [Full Text] [Related]
12. Pharmacology of zolimidine (2-(p-methylsulfonylphenyl)-imidazo (1,2-a) pyridine) a new non-anticholinergic gastroprotective agent. I) Protective activity against experimental neurogenic gastric ulcers and other pharmacologic properties.
Murmann W; Carminati GM; Cattaneo R
Panminerva Med; 1974 Oct; 16(10):301-20. PubMed ID: 4155794
[No Abstract] [Full Text] [Related]
13. Pharmacology of zolimidine (2-(p-methylsulfonylphenyl)-imidazo (1,2-a) pyridine) a new non-anticholinergic gastroprotective agent. II) Protective activity against drug-induced experimental ulcers.
Murmann W; Carminati GM; Cattaneo R
Panminerva Med; 1974 Oct; 16(10):321-34. PubMed ID: 4155795
[No Abstract] [Full Text] [Related]
14. Editorial: Steroid induced peptic ulcer.
Majumdar SK
J Indian Med Assoc; 1973 Jun; 60(12):471. PubMed ID: 4202469
[No Abstract] [Full Text] [Related]
15. [Roxatidine in the treatment of gastroduodenal mucosal lesions in hepatic cirrhosis].
Sardini C; Ventura P; Abbati GL; Rigo G; Cioni G; Cristani A; Tincani E; Ventura E
Recenti Prog Med; 1994 Nov; 85(11):517-20. PubMed ID: 7855384
[TBL] [Abstract][Full Text] [Related]
16. [Our experience in the therapy of gastrointestinal diseases (peptic ulcer and gastroduodenitis) with methachlopramide].
Arias Vallejo E; Galán Navarro JL
Rev Clin Esp; 1967 Feb; 104(3):248-55. PubMed ID: 5597813
[No Abstract] [Full Text] [Related]
17. Mucopoietic activity of zolimidine: is its effect through cellular turnover or by modification of the gastric mucosal blood flow?
Abate S; Fresini A; Ferulano GP; Danzi M; Califano G
Int J Tissue React; 1982; 4(4):319-24. PubMed ID: 6220992
[TBL] [Abstract][Full Text] [Related]
18. [Enzymologic aspects of the gastric mucosa in humans with chronic gastritis associated with gastric cancer and gastric and duodenal ulcer].
Dragoncea C; Aposteanu G
Med Interna (Bucur); 1965 Sep; 17(9):1063-7. PubMed ID: 5843756
[No Abstract] [Full Text] [Related]
19. [Clinical evaluation of a new synthetic preparation (zolimidine) in the treatment of gastroduodenal diseases].
Rivero Fontán JL; Barranco Jiménez M; Gómez Parra M
Rev Esp Enferm Apar Dig; 1972 Jul; 38(1):103-26. PubMed ID: 5069487
[No Abstract] [Full Text] [Related]
20. [Effects of propaxoline therapy on gastroduodenal inflammation. Radiological, endoscopic, bioptic and functional studies of the stomach and duodenum].
Gasbarrini G; Faggioli F; Melchionda N; Miglio F; Zanetti A
Minerva Med; 1970 Sep; 61(71):3643-66. PubMed ID: 5454749
[No Abstract] [Full Text] [Related]
[Next] [New Search]
